Literature DB >> 30281114

Intravenous Triacylglycerol Infusion Promotes Ceramide Accumulation and Hepatic Steatosis in Dairy Cows.

J Eduardo Rico1,2, Sarah L Giesy1, Norman J Haughey3, Yves R Boisclair1, Joseph W McFadden1.   

Abstract

Background: Increased plasma free fatty acids (FFAs) impair insulin sensitivity in dairy cows via unknown mechanisms. In nonruminants, saturated FFAs upregulate the hepatic synthesis and secretion of ceramide, which inhibits insulin action. Objective: We aimed to determine whether an increase in plasma FFAs promotes hepatic and plasma ceramide accumulation in dairy cows.
Methods: Six nonpregnant, nonlactating Holstein cows were used in a study with a crossover design and treatments consisting of intravenous infusion of either saline (control) or triacylglycerol emulsion (TG; 20 g/h) for 16 h. The feeding level was set at 120% of energy requirements. Blood was collected at regular intervals and liver was biopsied at 16 h. Ceramides, monohexosylceramides (Glc/Gal-Cer), lactosylceramides (LacCer), and sphingomyelins (SMs) in plasma and liver were profiled. Hepatic expression of ceramide synthases was determined. Data were analyzed with the use of mixed models, regressions, and Spearman rank correlations.
Results: After 16 h of infusion, plasma FFA concentrations were >5-fold and liver triacylglycerol concentrations were 4-fold greater in TG cows, relative to control. Plasma total and very long-chain ceramide (e.g., C24:0-ceramide) concentrations increased ∼4-fold in TG over control by hour 16 of infusion, while C16:0-ceramide were not modified by TG. Infusion of TG increased plasma Glc/Gal-Cer (e.g., C16:0-Glc/Gal-Cer, 4-fold by hour 16) relative to control, but did not alter LacCer or SM concentrations. Hepatic ceramide concentrations increased with TG relative to control (e.g., C24:0-ceramide by 1.7-fold). Hepatic expression of ceramide synthase 2 was 60% greater after TG infusion compared with the control. Circulating ceramides were related to circulating FFA and hepatic triacylglycerol concentrations (e.g., C24:0-ceramide, ρ = 0.73 and 0.80, respectively; P < 0.001).
Conclusion: Hepatic ceramide synthesis is associated with elevations in circulating FFAs and hepatic triacylglycerol during the induction of hyperlipidemia in dairy cows. This work supports the emerging evidence for the role of ceramide during hepatic steatosis and insulin antagonism in cows.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 30281114     DOI: 10.1093/jn/nxy155

Source DB:  PubMed          Journal:  J Nutr        ISSN: 0022-3166            Impact factor:   4.798


  4 in total

1.  Fibroblast growth factor-21 improves insulin action in nonlactating ewes.

Authors:  Cassandra L Lamb; Sarah L Giesy; Molly M McGuckin; James W Perfield; Anthony Butterfield; Mohammed Moniruzzaman; Norman J Haughey; Joseph W McFadden; Yves R Boisclair
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2022-01-12       Impact factor: 3.619

2.  Effects of acute intravenous lipopolysaccharide administration on the plasma lipidome and metabolome in lactating Holstein cows experiencing hyperlipidemia.

Authors:  Awais Javaid; Feiran Wang; Erin A Horst; M Elena Diaz-Rubio; Lin F Wang; Lance H Baumgard; Joseph W McFadden
Journal:  Metabolomics       Date:  2022-09-19       Impact factor: 4.747

3.  Mid- to late-gestational maternal nutrient restriction followed by realimentation alters development and lipid composition of liver and skeletal muscles in ovine fetuses.

Authors:  Brandon I Smith; Amanda Liefeld; Manuel A Vásquez-Hidalgo; Kimberly A Vonnahme; Anna T Grazul-Bilska; Kendall C Swanson; Neha Mishra; Sarah A Reed; Steven A Zinn; Kristen E Govoni
Journal:  J Anim Sci       Date:  2021-12-01       Impact factor: 3.338

Review 4.  The Role of Mitochondrial Quality Control in Cognitive Dysfunction in Diabetes.

Authors:  Jian-Sheng Luo; Jia-Qi Ning; Zhuo-Ya Chen; Wen-Jing Li; Rui-Ling Zhou; Ru-Yu Yan; Meng-Jie Chen; Ling-Ling Ding
Journal:  Neurochem Res       Date:  2022-06-04       Impact factor: 4.414

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.